Management of HIV infection the potential role of the lamivudine/zidovudine combination formulation

Disease Management and Health Outcomes

Volumn 4, Issue 5, 1998, Pages 277-293

  Perry, Caroline M ^a   Balfour, Julia A Barman ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ANEMIA; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORBIDITY; NEUTROPENIA; REVIEW;

EID: 0031743430     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-199804050-00004     Document Type: Article

References (3)

1. Glaxo Wellcome USA. Lamivudine/zidovudine prescribing information. 1998
2. Perry CM, Faulds D. Lamivudine: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 1997 Apr; 53:657-80
3. Wilde MI, Langtry HD. Zidovudine: an update of its pharma-codynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1993; 46: 515-78